Your Drug Was Approved Last Year. Why It Needs to Be Approved Again.

The approval letter said it clearly. Your insurer had reviewed the clinical evidence, the diagnosis, the prescribing physician's rationale, and had authorized your biologic for the next six months. You filled the prescription. The treatment worked.

Six months later, none of that matters.

The approval has expired. Your insurer requires a new one. Your physician's office needs to resubmit documentation. The drug that was working, for the condition that hasn't changed, for the patient whose labs confirm improvement, requires authorization as if none of it happened before.

This is the re-authorization cycle, and it is not a bureaucratic oversight. It is an insurance industry mechanism built to serve specific financial purposes, operating at the expense of people who are, by most clinical measures, doing well.

How the Cycle Works

Prior authorizations for biologics, intravenous immunoglobulin (IVIG), and most specialty drugs are not issued indefinitely. They are granted for a defined period, typically six to twelve months, after which the insurer treats the coverage as lapsed. If no renewal is submitted and approved before the authorization expires, the claim will be rejected.

For patients on maintenance biologics, this is a recurring reality. A patient with rheumatoid arthritis who has been stable on adalimumab for three years will have cycled through multiple authorizations. A patient with relapsing-remitting multiple sclerosis on natalizumab receives no immunity from the renewal requirement because the drug has kept their disease quiet. The stability is not evidence of resolution. It is evidence of efficacy. But the insurer's authorization clock does not distinguish between the two.

Each renewal requires the prescribing physician's office to resubmit clinical documentation: recent labs, functional status assessments, updated treatment notes, evidence of ongoing medical necessity. For a condition that is, by definition, being managed, the documentation requirement demands proof that a stable patient continues to require the drug that is keeping them stable.

What Insurers Gain

The re-authorization cycle serves several functions from an insurer's perspective, none of which are clinical.

The most direct is formulary control. At each renewal point, the insurer can assess whether a lower-cost alternative has become available since the original authorization. If a biosimilar has launched, or if a different agent is now preferred on the plan's formulary, the insurer can require the patient to trial the alternative before renewing coverage for the original drug. The re-authorization window is, structurally, a mandatory review of whether a cheaper option exists.

The second function is utilization control. A subset of authorization renewals will not be submitted in time, either because the patient doesn't know the expiration date, because the physician's office fails to act on it, or because paperwork is delayed. Coverage lapses. The patient misses doses. The insurer has no obligation to cover a drug that was not authorized at the time of dispensing. A small percentage of lapses, multiplied across a large membership, produces meaningful cost savings for the insurer.

The third function is what insurance policy analysts have described as an opportunity for non-medical switching. A 2022 analysis in the American Journal of Managed Care found that formulary-driven switching at renewal, not physician-initiated switching, was the predominant mechanism by which patients on biologics were transitioned to alternative agents. The re-authorization period is when that switch is easiest to require.

The Clinical Cost

What happens to patients when re-authorization fails, whether through denial or lapse, has been documented across multiple clinical specialties.

A 2023 study in Arthritis and Rheumatology found that treatment interruptions in patients with rheumatoid arthritis receiving biologic therapy were associated with significantly increased rates of disease flares and joint damage progression. Patients who experienced gaps of more than 30 days showed measurably worse outcomes than those who maintained continuous therapy.

In inflammatory bowel disease, the evidence is similarly clear. Research published in Inflammatory Bowel Diseases in 2021 found that biologic treatment interruptions in patients with Crohn's disease were associated with increased rates of hospitalization and corticosteroid use. The study noted that re-authorization-related gaps were among the most common causes of unintended treatment interruption.

In neurology, a 2020 report in Multiple Sclerosis and Related Disorders documented cases of rebound disease activity in patients with MS following IVIG or biologic interruption, including cases in which a gap of several weeks was followed by severe relapse requiring hospitalization.

The pattern is consistent: for patients on maintenance biologic or specialty therapy, treatment continuity is not a convenience. Interruption carries documented clinical risk. The re-authorization cycle creates systematic, recurring interruption risk for this population.

The AMA Position

The American Medical Association has tracked the administrative burden and clinical harm from prior authorization requirements for several years. In its 2024 prior authorization survey, the AMA found that 94% of physicians reported that prior authorization requirements had led to delays in care, and 89% said the process had caused harm to patients in their practice. More than one in four physicians said a patient had experienced a serious adverse event as a result of prior authorization delay.

The AMA has called for substantial reform, including legislation to reduce renewal requirements for stable patients and to implement what policy advocates call "gold carding." Gold carding would exempt physicians with a strong track record of prescribing appropriateness from initial and renewal authorization requirements. Several states have passed versions of this legislation, though implementation and enforcement have varied significantly.

Gold carding does not eliminate re-authorization. It is a partial solution, and it applies only in states with operative laws and only with physicians who qualify. For most patients on specialty drugs, the cycle continues.

What to Do Before Your Renewal Date

The re-authorization expiration date is on your approval letter. It is usually printed clearly, though it may appear under a header reading "Authorization Period" or "Approval Valid Through." If you do not have the letter, your specialty pharmacy or your insurer's member services line can tell you the date.

Once you have it, work backward. Physician offices in high-volume practices commonly take three to four weeks to prepare and submit renewal documentation, and insurer review timelines for standard (non-urgent) prior authorization requests run up to 15 business days under ACA regulations. Sixty to ninety days before expiration is the recommended window to begin the renewal process. Ask your prescriber's office explicitly what date they plan to submit.

When your renewal is under review, document that your treatment is working. Recent labs, patient-reported symptom scores, any functional assessments your physician has conducted, and a dated note from your physician confirming continued clinical benefit all strengthen the renewal case. This documentation serves two purposes: it supports the initial approval, and it forms the foundation of an appeal if the renewal is denied.

If the renewal is denied, you are not starting from nothing. A denial at renewal is the same procedurally as an initial denial, with the same right to appeal, the same timeline requirements, and the same access to external independent review. An appeal for a renewal denial has additional weight because it can document continuous treatment, established clinical response, and the risk of interruption, a risk the peer-reviewed literature supports clearly.

If you receive a renewal denial and need help building the appeal documentation, Ellen can help you prepare it.

The Approval Window Is Not Your Doctor's Problem Alone

The re-authorization cycle works partly because no one person owns the tracking responsibility. The patient assumes the doctor's office is watching the date. The doctor's office assumes the specialty pharmacy will flag it. The specialty pharmacy assumes the insurer will notify the member. The insurer requires renewal and waits.

The patient who ends up without coverage is the one who believed the system would catch it.

It will not. Track your date. Give your physician's office a 90-day window. Document everything. And if the renewal fails, treat the appeal as the primary task it is, because the literature is clear about what happens when it doesn't get filed.

Sources: American Medical Association 2024 Prior Authorization Physician Survey; Arthritis and Rheumatology (2023), biologic treatment interruption and outcomes in RA; Inflammatory Bowel Diseases (2021), biologic interruption and hospitalization risk in Crohn's disease; Multiple Sclerosis and Related Disorders (2020), rebound activity following treatment gaps; American Journal of Managed Care (2022), formulary-driven non-medical switching in biologic-treated patients; ACA 45 CFR 147.138, prior authorization timeline requirements.